COSMOS Pharmaceutical Corporation (3349.T)

Better than 3141.T's revenue growth rate of 5.56%.

Better than 3141.T's ebitda of 53.31B.

Better than 3141.T's ebitda margin of 4.15%.

Better than 3141.T's ebit of 27.06B.

Better than 3141.T's ebit margin of 2.11%.

Better than 3141.T's depreciation of 26.25B.

Better than 3141.T's total cash of 35.01B.

Better than 3141.T's cash as percentage of revenue of 2.72%.

Better than 3141.T's receivables of 68.34B.

Better than 3141.T's receivables as percentage of revenue of 5.32%.

Better than 3141.T's inventories of 149.01B.

Better than 3141.T's inventories as percentage of revenue of 11.60%.

Better than 3141.T's capital expenditure of -10.61B.

Better than 3141.T's capex as percentage of revenue of -0.83%.

Better than 3141.T's diluted shares outstanding of 207.25M.

Better than 3141.T's total debt of 81.25B.

Better than 3141.T's total equity of 533.45B.

Better than 3141.T's total capital of 614.70B.

Better than 3141.T's debt weighting of 13.22%.

Better than 3141.T's equity weighting of 86.78%.

Better than 3141.T's ebiat of 15.40B.

Better than 3141.T's unlevered free cash flow of 22.84B.

Better than 3141.T's net debt of 46.24B.